Limb salvage of an infant with infantile fibrosarcoma using TRK inhibitor larotrectinib [PDF]
Ecancermedicalscience, 2023 Infantile fibrosarcoma (IFS) is an extremely rare locally aggressive soft tissue tumour of childhood. Primary therapy involves complete surgical resection with or without chemotherapy.
Shubham Sahni +3 more
semanticscholar +2 more sources
Discovery of a rare GKAP1-NTRK2 fusion in a pediatric low-grade glioma, leading to targeted treatment with TRK-inhibitor larotrectinib [PDF]
Cancer Biol Ther, 2021 Here we report a case of an 11-year-old girl with an inoperable tumor in the optic chiasm/hypothalamus, who experienced several tumor progressions despite three lines of chemotherapy treatment.
L. Deland +11 more
semanticscholar +2 more sources
Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents [PDF]
Br J CancerWhile NTRK fusion-positive cancers can be exquisitely sensitive to first-generation TRK inhibitors, resistance inevitably occurs, mediated in many cases by acquired NTRK mutations.
Paola Roa +21 more
semanticscholar +2 more sources
A Tumor-Agnostic NTRK (TRK) Inhibitor
Cell, 2019 Larotrectinib is a small-molecule kinase inhibitor that targets NTRK fusions that occur in multiple types of cancer. Its FDA approval represents the first instance of a treatment indication being designated "tumor-agnostic" from the outset, being based on actionable genomic insights. To view this Bench to Bedside, open or download the PDF.
Franklin W, Huang, Felix Y, Feng
openaire +3 more sources
Definitions, 2020 An orally available liquid suspension containing the tropomyosin receptor kinase (Trk) inhibitor AZD6918 with potential antineoplastic activity. AZD6918 binds to Trk, thereby preventing neurotrophin-Trk interaction and Trk activation, and may eventually ...
openaire +2 more sources
Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancer [PDF]
Expert Review of Clinical Pharmacology, 2019 Introduction: Detecting oncogenic drivers across multiple cancers has brought about a shift toward a more targeted therapeutic approach. Neurotrophic tyrosine receptor kinase (NTRK) gene fusions are genomic rearrangements containing the kinase domain of one of three tropomyosin receptor kinases (TRK) and a dimerization domain contributed by another ...
Noah, Federman, Ray, McDermott
openaire +3 more sources
Pan-TRK Inhibitor ONO-7579 [PDF]
Definitions, 2020 An orally bioavailable, selective pan-tropomyosin-related-kinase (tyrosine receptor kinase; TRK) inhibitor, with potential antineoplastic activity. Upon oral administration, ONO-7579 specifically targets and binds to TRK and fusion proteins containing ...
openaire +2 more sources
ALK/TRK Inhibitor TSR-011 [PDF]
Definitions, 2020 An orally available inhibitor of both the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the tropomyosin-related kinases (TRK) TRKA, TRKB, and TRKC, with potential antineoplastic activity.
openaire +2 more sources
Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma carrying the characteristic ETV6-NTRK3 gene fusion [PDF]
Ann Oncol, 2019 Background The ETV6-NTRK3 gene fusion is present in the majority of cases of infantile fibrosarcoma (IFS) and acts as a potent oncogenic driver. We report the very rapid, complete, and sustained response of an advanced, chemotherapy-refractory, recurrent
S. Bielack +17 more
semanticscholar +2 more sources
TRK Inhibitor Shows Early Promise [PDF]
Cancer Discovery, 2016 Abstract Results from a phase I study show that the TRK inhibitor LOXO-101 is well tolerated and effective, with patients whose tumors bear NTRK fusions responding well and durably to this targeted therapy.
openaire +2 more sources